HealthPlexus.net

Peptic Ulcer Disease in Older Adults - letter

Disclaimer:  While every attempt is made to ensure that drug dosages provided within the text of this journal and the website are accurate, readers are urged to check drug package inserts before prescribing. Views and opinions in this publication and the website are not necessarily endorsed by or reflective of those of the publisher.

Peptic Ulcer Disease in Older Adults - letter


To the Editor:

Could the authors of the February 2007 article “Peptic Ulcer Disease in Older Adults” (Geriatrics Aging 2007;vol. 10, no. 2:77-83) please comment in a bit more detail on the evidence supporting the statement that “it would be prudent not only to switch to a COX-2 inhibitor but also to add a PPI” (p. 82, section on NSAIDs, last sentence).

Toronto Physician

Drs. Constantine A. Soulellis and Carlo A. Fallone respond:

To our knowledge, the issue of concurrent usage of COX-2 inhibitors and proton pump inhibitors (PPIs) has been explored in the literature only once before;1,2 this was a negative study that failed to demonstrate superiority of COX-2 inhibitors/PPIs over nonselective NSAIDs/PPIs in high-risk GI patients. However, we would like to disclose that we are privy to the results of a large retrospective cohort study conducted at McGill University and the University of Montreal that included over two million registered prescriptions for COX-2 inhibitors, nonselective NSAIDS, PPIs, and every combination thereof. The findings, to be published in an upcoming issue of Arthritis and Rheumatism (July 2007),3 demonstrate a clear reduction in the studied outcome (hospitalizations from perforated or bleeding ulcers) for COX-2 inhibitors plus PPIs compared to COX-2 inhibitors alone for ages greater than 75. COX-2 inhibitors and PPIs were also found to be superior to nonselective NSAIDs and PPIs for the same measured outcomes.

I hope this explanation is satisfactory for your readers. Again, thank you kindly for affording us the opportunity to contribute to Geriatrics & Aging.

Regards,
C. A. Fallone and C. A. Soulellis

References

  1. Cryer B. A COX-2-specific inhibitor plus a proton-pump inhibitor: is this a reasonable approach to reduction in NSAIDs’ GI toxicity? Am J Gastroenterol 2006;101:711-3.
  2. Scheiman JM, Yeomans ND, Talley NJ et al. Prevention of ulcers by esomeprazole in at-risk patients using non-selective NSAIDs and COX-2 inhibitors.  Am J Gastroenterol 2006;101:701-10.
  3. Rahme E, Barkun AN, Toubouti Y, et al. Do proton pump inhibitors confer additional gastrointestinal protection in patients given celecoxib? Arthritis Rheum 2007;57. In press.
Related Terms: Other, letter